Hydroxychloroquine COVID trial fizzles: only 17 patients enrolled

NCT ID NCT04345692

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether hydroxychloroquine (a malaria drug) could help hospitalized COVID-19 patients recover faster. It planned to enroll 350 people but was stopped early with just 17 participants. Because it ended so early, we cannot say whether the drug works or is safe for this use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hydroxychloroquine (Plaquenil)

What this could lead to

If it had worked, this could have pointed toward a cheap, widely available treatment for hospitalized COVID-19 patients.

What could go wrong

The trial was terminated early with only 17 participants, far short of the planned 350. Results are too limited to draw any conclusions, and earlier studies showed mixed or no benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States